Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITF2357 for mucosal healing in moderate-to-severe active Crohn's disease
NL-OMON31172Phase 2Not yet recruiting
- Sponsor
- Italfarmaco
- Start
- Jul 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing ITF2357 with Placebo (2 arms). Primary endpoint: Rate of complete mucosal healing at week 8. Planned start Jul 2007; status: not yet recruiting.
02
Drugs
givinostat
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON31172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31172.